Facebook Linkedin RSS Twitter Youtube
Home 2024

Biogen

FDA Approves Lilly’s Amyloid-Targeting Kisunla for Early Alzheimer’s
Drug Discovery

FDA Approves Lilly’s Amyloid-Targeting Kisunla for Early Alzheimer’s

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing
Drug Discovery

Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financing

StockWatch: Biogen Q1 Results Beat Expectations, for a Change
Drug Discovery

StockWatch: Biogen Q1 Results Beat Expectations, for a Change

Prime Editing for Isogenic iPSCs, PRINT, Universal In Vivo CAR T Editing, Biogen Q4 Results Disappoint; Andrea Choe
Bioprocessing

Prime Editing for Isogenic iPSCs, PRINT, Universal In Vivo CAR T Editing, Biogen Q4 Results Disappoint; Andrea Choe

StockWatch: Biogen’s Q4 Results Disappoint Analysts
Drug Discovery

StockWatch: Biogen’s Q4 Results Disappoint Analysts

Antibodies Take Center Stage in Alzheimer’s
Drug Discovery

Antibodies Take Center Stage in Alzheimer’s

As Biopharma Giants Reshape the Field, Cognition Therapeutics Sees a Place for Its Alzheimer’s Drug
Drug Discovery

As Biopharma Giants Reshape the Field, Cognition Therapeutics Sees a Place for Its Alzheimer’s Drug

Conscious Re-Coupling: M&A Comes Back Surely, If Slowly
Bioprocessing

Conscious Re-Coupling: M&A Comes Back Surely, If Slowly

Biogen to Acquire Reata for $7.3B, Adding to Neuro Drug Portfolio
Drug Discovery

Biogen to Acquire Reata for $7.3B, Adding to Neuro Drug Portfolio

StockWatch: Layoffs Extend Biogen’s Stock Skid
Drug Discovery

StockWatch: Layoffs Extend Biogen’s Stock Skid

123...21Page 1 of 21
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.